Eli Lilly’s oral GLP-1 candidate, orforglipron, faces a delay in approval, impacting the company’s stock value. Novo Nordisk advances in the weight loss market with an approved oral drug, Wegovy. The FDA extends the review time for orforglipron, now expected to be decided on by April 10. Novo Nordisk gains an advantage with more time to capture market share before Eli Lilly’s potential launch. Despite setbacks, Eli Lilly remains strong in the weight loss market with an attractive pipeline and promising financial results. The market may have overreacted to the delay, making Eli Lilly shares a buy.

Read more at Yahoo Finance: Should You Dump Eli Lilly’s Shares After This Setback?